Sugen's Modest Financing Victory
Sugen's strategy of a private placement of senior convertible debt solves a dilemma for biotechs that once had hot technologies but now find themselves lost with products in the early stages of clinical trials--how to raise money without diluting an already depressed stock price.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.